Watching your hair grow back with alopecia areata brings real relief, but for a lot of people it also comes with a quiet worry about losing it all over again. Right now, holding on to that regrowth usually means staying on treatment for the long haul, which is why new findings on an investigational drug called rezpegaldesleukin are getting so much attention.
As reported by Dermatology Times, the results come from a mid-stage clinical trial of people with severe to very severe alopecia areata who hadn’t tried a JAK inhibitor or another biologic. Instead of shutting down inflammation, the drug boosts regulatory T cells, which work like the immune system’s brakes. The hope is that this helps calm the immune attack on hair follicles that causes the hair loss.
Patients who were still regrowing hair at 36 weeks could keep going for another 16 weeks, and by the one-year mark, about 30 percent of them had reached at least 80 percent scalp coverage. Their results hadn’t leveled off yet, either, so more time on the drug may mean even more hair. These extension findings come from patients who had already responded to treatment.
The bigger surprise came after treatment ended, when six of eight patients who had reached that level of regrowth still had it four months later and five still had it at six months. The group was small, but some of those patients actually saw more hair come back while off the drug. The data were presented at a medical meeting and announced by the drug’s developer.
That’s a real difference from the JAK inhibitor pills currently available for alopecia areata, which generally have to be taken continuously to keep regrowth in place, according to Indianapolis dermatologist David Rosmarin, MD, chair of the Department of Dermatology at Indiana University School of Medicine, who presented the trial’s results. He also pointed out what losing that progress can mean for patients. “For someone who may take 3 years to regrow their hair,” he said, “for them to start losing it again is very devastating.”
So far, the drug’s safety through a year of treatment has been described as favorable, and the same medication is also being studied for eczema. A larger, late-stage trial of about 850 people with alopecia areata is expected to begin in early 2027, so it isn’t available yet. If you’re living with alopecia areata now, it’s worth talking with your dermatologist about the options that exist today, knowing that treatments that don’t demand such constant commitment could eventually be on the way.
